Laboratory identification of factor inhibitors: An update

Pathology

Volumn 44, Issue 4, 2012, Pages 293-302

  Kershaw, Geoffrey ^a   Favaloro, Emmanuel J ^b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

APTT; Bethesda assay; Factor inhibitors; Lupus inhibitor; Mixing tests; Replacement therapy

Indexed keywords

EID: 84863645780     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e328353254d     Document Type: Article

References (67)

1. Kershaw G, Jayakodi D, Dunkley S. Laboratory identification of factor inhibitors: the perspective of a large tertiary hemophilia center. Semin Thromb Hemost 2009; 35: 760-8.
2. Kasper CK, Aledort LM, Counts RB, et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869-72.
3. Dimichele D. Inhibitor treatment in haemophilias A and B: inhibitor diagnosis. Haemophilia 2006; 12 (Suppl 6): 37-42. (Pubitemid 44752488)
4. White GC, Kempton CL, Grimsley A, Nielsen B, Roberts HR. Cellular immune responses in hemophilia: why do inhibitors develop in some, but not all hemophiliacs? J Thromb Haemost 2005; 3: 1676-81. (Pubitemid 41716553)
5. Gouw SC, van den Berg HM. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment. Semin Thromb Hemost 2009; 35: 723-34.
6. Ananyeva NM, Lee TK, Jain N, Shima M, Saenko EL. Inhibitors in hemophilia A: advances in elucidation of inhibitory mechanisms and in inhibitor management with bypassing agents. Semin Thromb Hemost 2009; 35: 735-51.
7. Key NS. Inhibitors in congenital coagulation disorders. Br J Haematol 2004; 127: 379-91. (Pubitemid 39539246)
8. Towfighi F, Gharagozlou S, Sharifian RA, et al. Comparative measurement of anti-factor VIII antibody by Bethesda assay and ELISA reveals restricted isotype profile and epitope specificity. Acta Haematol 2005; 114: 84-90. (Pubitemid 41160935)
9. Oldenburg J, Tuddenham E. Inhibitors to factor VIII-molecular basis. In: Lee C, Berntorp E, Hoots KW, editors. Textbook of Hemophilia. Oxford: Blackwell Publishing, 2005; 59-63.
10. Lusher J. Natural history of inhibitor development in children with severe hemophilia A treated with FVIII products. In: Lee C, Berntorp E, Hoots KW, editors. Textbook of Hemophilia. Oxford: Blackwell Publishing, 2005; 34-8.
11. Gouw SC, Berg HMVD, Cessie SL, Bom JGVD. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost 2007; 5: 1383-90. (Pubitemid 46965364)
12. Lillicrap D, Nair SC, Srivastava A, Rodeghiero F, Pabinger I, Federici AB. Laboratory issues in bleeding disorders. Haemophilia 2006; 12 (Suppl 3): 68-75.
13. Dunkley S, Kershaw G, Young G, et al. Rituximab treatment of mild haemophilia Awith inhibitors: a proposed treatment protocol. Haemophilia 2006; 12: 663-7. (Pubitemid 44697539)
14. Franchini M, Favaloro EJ, Lippi G. Mild hemophilia A. J Thromb Haemost 2010; 8: 421-32.
15. Ma AD, Carrizosa D. Acquired factor VIII inhibitors: pathophysiology and treatment. Hematology Am Soc Hematol Educ Program 2006:432-7.
16. Kasper CK, Ewing NP. Acquired inhibitors of plasma coagulation factors. J Med Technol 1986; 38: 431-9. (Pubitemid 16073720)
17. Mannucci PM, Payvandi F. Autoimmune hemophilia at rescue. Haematologica 2009; 94: 459-61.
18. Collins PW, Hirsch S, Baglin TP, et al. UK Haemophilia Centre Doctors' Organisation Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood 2007; 109: 1870-7. (Pubitemid 46348182)
19. Tay L, Duncan E, Singhal D, et al. Twelve years of experience of acquired hemophilia A: trials and tribulations in south Australia. Semin Thromb Hemost 2009; 35: 769-77.
20. Green D, Lechner K. A survey of 215 non-hemophiliac patients with inhibitors to factor VIII. Thromb Haemost 1981; 45: 200-3. (Pubitemid 11081028)
21. Warrier I. Inhibitors in hemophilia B. In: Lee C, Berntorp E, Hoots KW, editors. Textbook of Hemophilia. Oxford: Blackwell Publishing, 2005.
22. Llung R, Petrini P, Tengborn L, Sjorin E. Haemophilia B mutations in Sweden: a population-based study of mutational heterogeneity. Br J Haemat 2001; 113: 81-6. (Pubitemid 32423306)
23. Brown SA. Treatment of inhibitors in hemophilia B. In: Lee C, Berntorp E, Hoots KW, editors. Textbook of Hemophilia. Oxford: Blackwell Publishing, 2005; 101-5.
24. Favaloro EJ, Posen J, Ramakrishna R, et al. Factor V inhibitors: rare or not so uncommon? A multilaboratory investigation. Blood Coag Fibrinolysis 2004; 15: 637-47. (Pubitemid 39612969)
25. Ang AL, Kuperan P, Ng CH, Ng HJ. Acquired factor Vinhibitor. A problem based systematic review. Thromb Haemost 2009; 101: 852-9.
26. Lippi G, Favaloro EJ, Montagnana M, Manzato F, Guidi GC, Franchini M. Inherited and acquired factor V deficiency. Blood Coag Fibrinolysis 2011; 22: 160-6.
27. Asselta R, Peyvandi F. Factor V deficiency. Semin Thromb Hemost 2009; 35: 382-9.
28. Bowman LJ, Anderson CD, Chapman WC. Topical recombinant human thrombin in surgical hemostasis. Semin Thromb Hemost 2010; 36: 477-84.
29. Duga S, Salomon O. Factor XI deficiency. Semin Thromb Hemost 2009; 35: 416-25.
30. de Moerloose P, Neerman-Arbez M. Congenital fibrinogen disorders. Semin Thromb Hemost 2009; 35: 356-66.
31. Lancellotti S, De Cristofaro R. Congenital prothrombin deficiency. Semin Thromb Hemost 2009; 35: 367-81.
32. Mariani G, Bernardi F. Factor VII deficiency. Semin Thromb Hemost 2009; 35: 400-6.
33. Menegatti M, Peyvandi F. Factor X deficiency. Semin Thromb Hemost 2009; 35: 407-15.
34. Karimi M, Bereczky Z, Cohan N, Muszbek L. Factor XIII deficiency. Semin Thromb Hemost 2009; 35: 426-38.
35. Coleman R, Favaloro EJ, Soltani S, Keng TB. Acquired von Willebrand Disease: Potential contribution of the VWF: CB to the identification of functionally inhibiting auto-antibodies to von Willebrand factor. J Thromb Haemost 2008; 4: 1051-2.
36. Federici AB. Clinical and molecular markers of inherited von Willebrand disease type 3: are deletions of the VWF gene associated with alloantibodies to VWF? J Thromb Haemost 2008; 6: 1726-8.
37. Franchini M, Lippi G, Favaloro EJ. Etiology and diagnosis of acquired von Willebrand syndrome. Clin Adv Hematol Oncol 2010; 8: 20-4.
38. Favaloro EJ. Laboratory testing in disseminated intravascular coagulation. Semin Thromb Hemost 2010; 36: 458-67.
39. Tripodi A. Laboratory testing for lupus anticoagulants: diagnostic criteria and use of screening, mixing, and confirmatory studies. Semin Thromb Hemost 2008; 34: 373-8.
40. Kessler C, Asatiani E. Acquired inhibitors to factor VIII. In: Lee C, Berntorp E, Hoots KW, editors. Textbook of Hemophilia. Oxford: Blackwell Publishing, 2005; 86-90.
41. Lossing T, Kasper C, Feinstein D. Detection of factor VIII inhibitors with the partial thromboplastin time. Blood 1977; 49: 793-7. (Pubitemid 8093475)
42. Kazmi MA, Pickering W, Smith MP, Holland LJ, Savidge GF. Acquired haemophilia A: errors in the diagnosis. Blood Coagul Fibronolysis 1998; 9: 623-8. (Pubitemid 28520160)
43. Favaloro EJ, Bonar R, Zebeljan D, Kershaw G, Marsden K. Laboratory investigation of lupus anticoagulants: mixing studies are sometimes required. J Thromb Haemost 2010; 8: 2828-31.
44. Bonar R, Favaloro EJ, Zebeljan D, et al. Evaluating laboratory approaches to the identification of lupus anticoagulants: A diagnostic challenge from the RCPA Haematology QAP. Pathology 2012; 44: 240-7.
45. Meijer P, Verbruggen B. The between-laboratory variation of factor VIII inhibitor testing: the experience of the external quality assessment program of the ECAT foundation. Semin Thromb Hemost 2009; 35: 786-93.
46. Verbruggen B, van Heerde WL, Laros-van Gorkom BA. Improvements in factor VIII inhibitor detection: From Bethesda to Nijmegen. Semin Thromb Hemost 2009; 35: 752-9.
47. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII: C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
48. Giles AR, Verbruggen B, Rivard GE, Teitel J, Walker I. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII: C inhibitors in the haemophilia A population of Canada. Thromb Haemost 1998; 79: 872-5. (Pubitemid 28163870)
49. Verbruggen B, van Heerde W, Novákovà I, Lillicrap D, Giles A. A 4% solution of bovine serum albumin may be used in place of factor VIII: C deficient plasma in the control sample in the Nijmegen Modification of the Bethesda factor VIII: C inhibitor assay. Thromb Haemost 2002; 88: 362-4. (Pubitemid 34873724)
50. Kitchen S, McCraw A. Diagnosis of Haemophilia and Other Bleeding Disorders: A Laboratory Manual. Quebec: World Federation of Hemophilia, 2000; 72-6.
51. Gadarowski JJ, Czapek EE, Ontiveros JD, Pedraza JL. Modification of the Bethesda assay for factor FVIII or IX inhibitors to improve efficiency. Acta Haematol 1998; 80: 134-8.
52. Siaka C, Rugeri L, Caron C, Goudemand J. A new ELISA assay for diagnosis of acquired von Willebrand Syndrome. Haemophilia 2003; 9: 303-8. (Pubitemid 36622033)
53. Guerin V, Ryman A, Velez F. Acquired von Willebrand disease: potential contribution of the von Willebrand factor collagen-binding to the identification of functionally inhibiting auto-antibodies to von Willebrand factor: a rebuttal. J Thromb Haemost 2008; 6: 1051-2. (Pubitemid 351689936)
54. Favaloro EJ, Bonar R, Duncan E, et al. (on behalf of the RCPA QAP in Haematology Haemostasis Committee)Identification of factor inhibitors by diagnostic haemostasis laboratories: A large multi-centre evaluation. Thromb Haemost 2006; 96: 73-8. (Pubitemid 44160873)
55. Favaloro EJ, Bonar R, Duncan E, et al. (on behalf of the RCPA QAP in Haematology Haemostasis Committee). Mis-identification of factor inhibitors by diagnostic haemostasis laboratories: recognition of pitfalls and elucidation of strategies. A follow up to a large multicentre evaluation. Pathology 2007; 39: 504-11. (Pubitemid 47454494)
56. Favaloro EJ, Bonar R, Kershaw G, Duncan E, Sioufi J, Marsden K (on behalf RCPA Haematology QAP Haemostasis Committee). Investigations from external quality assurance programs reveal a high degree of variation in the laboratory identification of coagulation factor inhibitors. Semin Thromb Hemost 2009; 35: 794-805.
57. Favaloro EJ, Bonar R, Kershaw G, Mohammed S, Duncan E, Marsden K (on behalf RCPA Haematology QAP Haemostasis Committee). Laboratory identification of factor VIII inhibitors in the real world: the experience from Australasia. Haemophilia 2010; 16: 662-70.
58. Kitchen S, Jennings I, Preston FE, Kitchen DP, Woods TA, Walker ID. Interlaboratory variation in factor VIII: C inhibitor assay results is sufficient to influence patient management: data from the UK national quality external assessment scheme for blood coagulation. Semin Thromb Hemost 2009; 35: 778-85.
59. Peerschke EI, Castellone DD, Ledford-Kraemer M, Van Cott EM, Meijer P; NASCOLA Proficiency Testing Committee. Laboratory assessment of factor VIII inhibitor titer: the North American Specialized Coagulation Laboratory Association experience. Am J Clin Pathol 2009; 131: 552-8.
60. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35. (Pubitemid 36874391)
61. Iorio A, Halimeh S, Holzhauer S, et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost 2010; 8: 1256-65.
62. Franchini M, Lippi G. Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review. Thromb Haemost 2010; 104: 931-40.
63. Franchini M, Tagliaferri A, Mengoli C, Cruciani M. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: A critical systematic review. Crit Rev Oncol Hematol 2012; 81: 82-93.
64. Mannucci PM. Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better. Blood Transfus 2010; 8: 288-91.
65. Franchini M. Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better. Blood Transfus 2010; 8: 292-6.
66. Strauss T, Lubetsky A, Ravid B, et al. Recombinant factor concentrates may increase inhibitor development: a single centre cohort study. Haemophilia 2011; 17: 625-9.
67. Aledort LM, Navickis RJ, Wilkes MM. Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies. J Thromb Haemost 2011; 9: 2180-92.